Literature DB >> 11822971

Atherosclerosis and inflammation.

John A Farmer1, Guillermo Torre-Amione.   

Abstract

The pathophysiology of coronary atherosclerosis is complex and multifactorial. The probability of the development of symptomatic coronary heart disease may be predicted by standard risk factor stratification involving hypertension, dyslipidemia, age, positive family history, and diabetes. However, risk factor stratification has been demonstrated to have significant limitations in the individual patient, which has generated a search for more specific and sensitive markers. Evidence is increasing that atherosclerosis is a disease characterized by inflammation, beginning with the earliest identifiable lesion (fatty streak) to the advanced vulnerable plaque. Clinical markers of inflammation, including C-reactive protein, modified low-density lipoprotein, homocysteine, tumor necrosis factor, and thermogenicity, have been identified as emerging risk factors that may add prognostic information in patient management. This review centers on inflammation as a potential pathogenetic factor in atherosclerosis and the role that clinical markers may play in the identification of patients at risk.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11822971     DOI: 10.1007/s11883-002-0031-5

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  17 in total

Review 1.  The inflamed plaque: cytokine production and cellular cholesterol balance in the vessel wall.

Authors:  S Fazio; M F Linton
Journal:  Am J Cardiol       Date:  2001-07-19       Impact factor: 2.778

2.  Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.

Authors:  M A Albert; E Danielson; N Rifai; P M Ridker
Journal:  JAMA       Date:  2001-07-04       Impact factor: 56.272

3.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

Authors:  P M Ridker; N Rifai; M Clearfield; J R Downs; S E Weis; J S Miles; A M Gotto
Journal:  N Engl J Med       Date:  2001-06-28       Impact factor: 91.245

4.  Increased local temperature in human coronary atherosclerotic plaques: an independent predictor of clinical outcome in patients undergoing a percutaneous coronary intervention.

Authors:  C Stefanadis; K Toutouzas; E Tsiamis; C Stratos; M Vavuranakis; I Kallikazaros; D Panagiotakos; P Toutouzas
Journal:  J Am Coll Cardiol       Date:  2001-04       Impact factor: 24.094

Review 5.  HDL and the inflammatory response induced by LDL-derived oxidized phospholipids.

Authors:  M Navab; J A Berliner; G Subbanagounder; S Hama; A J Lusis; L W Castellani; S Reddy; D Shih; W Shi; A D Watson; B J Van Lenten; D Vora; A M Fogelman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-04       Impact factor: 8.311

6.  Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes.

Authors:  S Ehara; M Ueda; T Naruko; K Haze; A Itoh; M Otsuka; R Komatsu; T Matsuo; H Itabe; T Takano; Y Tsukamoto; M Yoshiyama; K Takeuchi; J Yoshikawa; A E Becker
Journal:  Circulation       Date:  2001-04-17       Impact factor: 29.690

7.  Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay.

Authors:  M Feldman; I Jialal; S Devaraj; B Cryer
Journal:  J Am Coll Cardiol       Date:  2001-06-15       Impact factor: 24.094

8.  C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris.

Authors:  H Koukkunen; K Penttilä; A Kemppainen; M Halinen; I Penttila; T Rantanen; K Pyörälä
Journal:  Ann Med       Date:  2001-02       Impact factor: 4.709

9.  Tumor necrosis factor receptor superfamily 12 may destabilize atherosclerotic plaques by inducing matrix metalloproteinases.

Authors:  S H Kim; W H Lee; B S Kwon; G T Oh; Y H Choi; J E Park
Journal:  Jpn Circ J       Date:  2001-02

10.  Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis.

Authors:  S Navalkar; S Parthasarathy; N Santanam; B V Khan
Journal:  J Am Coll Cardiol       Date:  2001-02       Impact factor: 24.094

View more
  10 in total

Review 1.  The physiology of lipoproteins.

Authors:  Thomas N Tulenko; Anne E Sumner
Journal:  J Nucl Cardiol       Date:  2002 Nov-Dec       Impact factor: 5.952

2.  Increased gene expression of scavenger receptors and proinflammatory markers in peripheral blood mononuclear cells of hyperlipidemic males.

Authors:  Gabriel A Bonaterra; Wulf Hildebrandt; Anne Bodens; Roland Sauer; Klaus A Dugi; Hans-Peter Deigner; Dan Turcanu; Helmut Heinle; Wulf Dröge; Jürgen Metz; Ralf Kinscherf
Journal:  J Mol Med (Berl)       Date:  2006-10-17       Impact factor: 4.599

3.  H. pylori-Induced Higher C-Reactive Protein in Obese African Americans.

Authors:  Nuzhat R Siddiqui; W Timothy Garvey; Mohammad A Khaled
Journal:  Artery Res       Date:  2009-02       Impact factor: 0.597

4.  Outdoor temperature is associated with serum HDL and LDL.

Authors:  Jaana I Halonen; Antonella Zanobetti; David Sparrow; Pantel S Vokonas; Joel Schwartz
Journal:  Environ Res       Date:  2010-12-18       Impact factor: 6.498

5.  Role of ultrasonic shear rate estimation errors in assessing inflammatory response and vascular risk.

Authors:  Jean K Tsou; Jie Liu; Abdul I Barakat; Michael F Insana
Journal:  Ultrasound Med Biol       Date:  2008-01-22       Impact factor: 2.998

6.  Effect of geraniol, a plant derived monoterpene on lipids and lipid metabolizing enzymes in experimental hyperlipidemic hamsters.

Authors:  Muthukumaran Jayachandran; Balaji Chandrasekaran; Nalini Namasivayam
Journal:  Mol Cell Biochem       Date:  2014-09-14       Impact factor: 3.396

7.  Relationship between CYP17A1 genetic polymorphism and coronary artery disease in a Chinese Han population.

Authors:  Chuan-Fang Dai; Xiang Xie; Yi-Ning Yang; Xiao-Mei Li; Ying-Ying Zheng; Zhen-Yan Fu; Fen Liu; Bang-Dang Chen; Min-Tao Gai; Yi-Tong Ma
Journal:  Lipids Health Dis       Date:  2015-03-07       Impact factor: 3.876

8.  Saliva/serum ghrelin, obestatin and homocysteine levels in patients with ischaemic heart disease.

Authors:  Nermin Kilic; Necati Dagli; Suleyman Aydin; Fazilet Erman; Yuksel Bek; Okhan Akin; S S Kilic; Haci Kemal Erdemli; Hasan Alacam
Journal:  Cardiovasc J Afr       Date:  2017 May/Jun       Impact factor: 1.167

9.  Ghrelin suppresses inflammation in HUVECs by inhibiting ubiquitin-mediated uncoupling protein 2 degradation.

Authors:  Ruolan Zhang
Journal:  Int J Mol Med       Date:  2017-05-05       Impact factor: 4.101

10.  Ghrelin Does not Alter Aortic Intima-Media Thickness and Adipose Tissue Characteristics in Control and Obese Mice.

Authors:  Zoya Tahergorabi; Bahman Rashidi; Majid Khazaei
Journal:  Iran J Basic Med Sci       Date:  2013-08       Impact factor: 2.699

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.